XERSXeris Biopharma Holdings Inc
$6.74
$0.24
(3.69%)
EarningsAug 6
Mkt Cap$1.12B
Vol1.42M
Fundamentals
Mkt Cap
$1.12B
Volume
-
52W High
$10.08
52W Low
$4.30
PE Ratio
99.24
Avg. Volume
1.79M
EPS (Annual)
$0.0032
Rev/Employee
$670,908.05
Earnings
Aug 06
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Xeris Biopharma Reports First Quarter 2026 Financial Results
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...
Business Wire
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider directly owned 1,193,173...
MarketBeat
Xeris Biopharma (XERS) to Release Earnings on Thursday
Xeris Biopharma (NASDAQ:XERS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-xeris-pharmaceuticals-inc-stock...
MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has earned an average rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy r...
MarketBeat
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...
Business Wire
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL trimmed its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 83.1% during the third quarter, according to its most recent filing with the Securities...
MarketBeat
Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS
Apella Capital LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2,359.0% during the fourth quarter, according to the company in its most recent...
MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an...
MarketBeat
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at...
MarketBeat
<
1
2
...
>